Cargando…

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA-approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lotan, Tamara L., Kaur, Harsimar B., Salles, Daniela, Murali, Sanjana, Schaeffer, Edward M., Lanchbury, Jerry S., Isaacs, William B., Brown, Robert, Richardson, Andrea L., Cussenot, Olivier, Cancel-Tassin, Geraldine, Timms, Kirsten M., Antonarakis, Emmanuel S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154637/ https://www.ncbi.nlm.nih.gov/pubmed/33462368 http://dx.doi.org/10.1038/s41379-020-00731-4

Ejemplares similares

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study
por: Karlsson, Questa, et al.
Publicado: (2021)

Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies)
por: Cancel-Tassin, Geraldine, et al.
Publicado: (2015)

The Genetic Complexity of Prostate Cancer
por: Compérat, Eva, et al.
Publicado: (2020)

Association of self-identified race and genetic ancestry with the immunogenomic landscape of primary prostate cancer
por: Vidotto, Thiago, et al.
Publicado: (2023)

Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma
por: Cussenot, Olivier, et al.
Publicado: (2013)

Homologous Recombination Deficiency (HRD) in Cutaneous Oncology
por: Akinjiyan, Favour A., et al.
Publicado: (2023)

Implementing HRD technology /
Publicado: (1999)

Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up
por: Cancel-Tassin, G., et al.
Publicado: (2021)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3
por: Schoebel, Stefan, et al.
Publicado: (2017)

Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity
por: Wang, Jufang, et al.
Publicado: (2011)

Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study
por: Zhang, Chenghai, et al.
Publicado: (2023)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Wip1 and ATM in tumor evolution: role for BRCA1
por: Filipponi, Doria, et al.
Publicado: (2013)

Prevalence of deleterious ATM germline mutations in gastric cancer patients
por: Huang, Dong-Sheng, et al.
Publicado: (2015)

Rare Germline Variants in ATM Are Associated with Chronic Lymphocytic Leukemia
por: Tiao, Grace, et al.
Publicado: (2017)

Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis
por: Su, Fengtao, et al.
Publicado: (2010)

Downregulation of ATM and BRCA1 Predicts Poor Outcome in Head and Neck Cancer: Implications for ATM-Targeted Therapy
por: Wang, Yu-Chu, et al.
Publicado: (2021)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer
por: Prodosmo, Andrea, et al.
Publicado: (2016)

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review
por: Tao, Mengyu, et al.
Publicado: (2020)

Endoplasmic Reticulum Degradation Requires Lumen to Cytosol Signaling: Transmembrane Control of Hrd1p by Hrd3p
por: Gardner, Richard G., et al.
Publicado: (2000)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Accurate tumor purity determination is critical for the analysis of homologous recombination deficiency (HRD)
por: Menzel, Michael, et al.
Publicado: (2023)

A Hrd way for MHC-II expression
por: Melo-Cardenas, Johanna, et al.
Publicado: (2015)

Night work and prostate cancer risk: results from the EPICAP Study
por: Wendeu-Foyet, Méyomo Gaelle, et al.
Publicado: (2018)

Biallelic BRCA Loss and Homologous Recombination Deficiency in Nonbreast/Ovarian Tumors in Germline BRCA1/2 Carriers
por: Wineland, Dylane, et al.
Publicado: (2023)

Erratum to: Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer
por: Prodosmo, Andrea, et al.
Publicado: (2016)

The TIP60-ATM axis regulates replication fork stability in BRCA-deficient cells
por: Schleicher, Emily M., et al.
Publicado: (2022)

Germline Mutations in BRCA1 and BRCA2 in Polish Families Predisposed to Breast and Ovary Cancers
por: Grzybowska, E., et al.
Publicado: (1999)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers
por: Ballot, Elise, et al.
Publicado: (2022)

ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing
por: Eeckhoutte, Alexandre, et al.
Publicado: (2020)

Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD)
por: Rempel, E., et al.
Publicado: (2022)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations
por: Kim, Kyung Hwan, et al.
Publicado: (2022)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ql9hmvj60phaj8kbhpu0q1kogq